Kidney and eye diseases: Common risk factors, etiological mechanisms, and pathways

Kidney International

Volumn 85, Issue 6, 2014, Pages 1290-1302

  Wong, Chee Wai ^a   Wong, Tien Yin ^a,b   Cheng, Ching Yu ^a,b   Sabanayagam, Charumathi ^a,b,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

age related macular degeneration; cataract; chronic kidney disease; diabetic retinopathy; retinal microvascular parameters

Indexed keywords

25 HYDROXYVITAMIN D; ADVANCED GLYCATION END PRODUCT; CANDESARTAN; CAPTOPRIL; COMPLEMENT FACTOR H; CYSTATIN C; ERYTHROPOIETIN; KLOTHO PROTEIN; VITAMIN D;

AGE; ATHEROSCLEROSIS; CATARACT; CHRONIC KIDNEY DISEASE; COMPLEMENT FACTOR H GENE; CONGENITAL DISORDER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; EYE DISEASE; GENETIC POLYMORPHISM; GLAUCOMA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; KLOTHO GENE; MICROALBUMINURIA; NONHUMAN; OBESITY; OCULAR SURFACE DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SMOKING; VITAMIN D DEFICIENCY; EYE DISEASES; GENETIC PREDISPOSITION; GENETICS; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

EYE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY DISEASES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84901926106     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.491     Document Type: Review

References (160)

1. 1. Wilkinson-Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: roles of angiotensin II and aldosterone. Peptides 2012; 36: 142-150.
2. Izzedine H, Bodaghi B, Launay-Vacher V et al. Eye and kidney: from clinical findings to genetic explanations. J Am Soc Nephrol 2003; 14: 516-529.
3. Zipfel PF, Heinen S, Jozsi M et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97-106.
4. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
5. US Renal Data System: USRDS 2007 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005. Available from http://www. usrds.org [accessed 02 May 2007] 2007.
6. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005; 15: 418-423.
7. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
8. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
9. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523.
10. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284.
11. Iseki K, Kohagura K, Sakima A et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res 2007; 30: 55-62.
12. Zhang L, Zhang P, Wang F et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis 2008; 51: 373-384.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
14. Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934-2941.
15. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
16. Barri YM. Hypertension and kidney disease: a deadly connection. Curr Cardiol Rep 2006; 8: 411-417.
17. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850.
18. Brancati FL, Whelton PK, Randall BL et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278: 2069-2074.
19. de Jong PE, Verhave JC, Pinto-Sietsma SJ et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26(SUPPL. 4): S21-S24.
20. Foster MC, Hwang SJ, Larson MG et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52: 39-48.
21. Klein R, Peto T, Bird A et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-495.
22. Tomany SC, Wang JJ, Van Leeuwen R et al. Risk factors for incident agerelated macular degeneration: pooled findings from 3 continents. Ophthalmology 2004; 111: 1280-1287.
23. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992; 110: 1701-1708.
24. Clemons TE, Milton RC, Klein R et al. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112: 533-539.
25. van Leeuwen R, Ikram MK, Vingerling JR et al. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003; 44: 3771-3777.
26. Hyman L, Schachat AP, He Q et al. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118: 351-358.
27. Wong TY, Duncan BB, Golden SH et al. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. Invest Ophthalmol Vis Sci 2004; 45: 2949-2954.
28. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol 2007; 52: 180-195.
29. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
30. Wong TY, Mitchell P. The eye in hypertension. Lancet 2007; 369: 425-435.
31. Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
32. van Leiden HA, Dekker JM, Moll AC et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002; 25: 1320-1325.
33. Sun C, Liew G, Wang JJ et al. Retinal vascular caliber, blood pressure, and cardiovascular risk factors in an Asian population: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci 2008; 49: 1784-1790.
34. Mitchell P, Smith W, Chey T et al. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997; 104: 712-718.
35. Mitchell P, Lee AJ, Rochtchina E et al. Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma 2004; 13: 319-326.
36. Bonomi L, Marchini G, Marraffa M et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000; 107: 1287-1293.
37. Weintraub JM, Willett WC, Rosner B et al. A prospective study of the relationship between body mass index and cataract extraction among US women and men. Int J Obes Relat Metab Disord 2002; 26: 1588-1595.
38. Chang JR, Koo E, Agron E et al. Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology 2011; 118: 2113-2119.
39. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010; 2: 247-257.
40. Moravski CJ, Kelly DJ, Cooper ME et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-1104.
41. Berka JL, Stubbs AJ, Wang DZ et al. Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 1995; 36: 1450-1458.
42. Yokota H, Nagaoka T, Mori F et al. Prorenin levels in retinopathy of prematurity. Am J Ophthalmol 2007; 143: 531-533.
43. Yokota H, Nagaoka T, Tani T et al. Higher levels of prorenin predict development of diabetic retinopathy in patients with type 2 diabetes. J Renin Angiotensin Aldosterone Syst 2011; 12: 290-294.
44. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-1393.
45. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
46. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
47. Vaajanen A, Vapaatalo H. Local ocular renin-angiotensin system-a target for glaucoma therapy? Basic Clin Pharmacol Toxicol 2011; 109: 217-224.
48. Reitsamer HA, Kiel JW. Relationship between ciliary blood flow and aqueous production in rabbits. Invest Ophthalmol Vis Sci 2003; 44: 3967-3971.
49. Shen F, Zhang L, Liu T. [Effects of angiotensin II on the 3H-TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells]. Yan Ke Xue Bao 2001; 17: 209-212.
50. Yang H, Hirooka K, Fukuda K et al. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 5800-5804.
51. Busch M, Franke S, Ruster C et al. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40: 742-755.
52. Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids 2012; 42: 1205-1220.
53. Franke S, Dawczynski J, Strobel J et al. Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg 2003; 29: 998-1004.
54. Ortwerth BJ, Chemoganskiy V, Mossine VV et al. The effect of UVA light on the anaerobic oxidation of ascorbic acid and the glycation of lens proteins. Invest Ophthalmol Vis Sci 2003; 44: 3094-3102.
55. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 4867-4874.
56. Yamagishi S, Fujimori H, Yonekura H et al. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 1999; 258: 353-357.
57. Xu X, Li Z, Luo D et al. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2003; 241: 56-62.
58. Canning P, Glenn JV, Hsu DK et al. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007; 2007: 51837.
59. Gerhardinger C, Dagher Z, Sebastiani P et al. The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 2009; 58: 1659-1667.
60. Brucklacher RM, Patel KM, VanGuilder HD et al. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics 2008; 1: 26.
61. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-628.
62. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389.
63. Laine M, Jarva H, Seitsonen S et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007; 178: 3831-3836.
64. Ufret-Vincenty RL, Aredo B, Liu X et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Invest Ophthalmol Vis Sci 2010; 51: 5878-5887.
65. Clark SJ, Bishop PN, Day AJ. Complement factor H and age-related macular degeneration: the role of glycosaminoglycan recognition in disease pathology. Biochem Soc Trans 2010; 38: 1342-1348.
66. Ehret GB, Munroe PB, Rice KM et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478: 103-109.
67. Schunkert H, Konig IR, Kathiresan S et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43: 333-338.
68. Bis JC, Kavousi M, Franceschini N et al. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet 2011; 43: 940-947.
69. Fornage M, Debette S, Bis JC et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011; 69: 928-939.
70. Ikram MK, Sim X, Jensen RA et al. Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. PLoS Genet 2010; 6: e1001184.
71. Mitchell GF, Verwoert GC, Tarasov KV et al. Common genetic variation in the 30-BCL11B gene desert is associated with carotid-femoral pulse wave velocity and excess cardiovascular disease risk: the AortaGen Consortium. Circ Cardiovasc Genet 2012; 5: 81-90.
72. Boger CA, Chen MH, Tin A et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol 2011; 22: 555-570.
73. Kottgen A, Pattaro C, Boger CA et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010; 42: 376-384.
74. Liu CT, Garnaas MK, Tin A et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 2011; 7: e1002264.
75. Devalliere J, Chatelais M, Fitau J et al. LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets alpha-parvin to control cell adhesion and migration. FASEB J 2012; 26: 2592-2606.
76. Takaki S, Morita H, Tezuka Y et al. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 2002; 195: 151-160.
77. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
78. Fon Tacer K, Bookout AL, Ding X et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24: 2050-2064.
79. Hu MC, Kuro-o M, Moe OW. Klotho and kidney disease. J Nephrol 2010; 23(SUPPL. 16): S136-S144.
80. Seddon JM, George S, Rosner B et al. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123: 774-782.
81. Bernardi RJ, Johnson CS, Modzelewski RA et al. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumorderived endothelial cells. Endocrinology 2002; 143: 2508-2514.
82. Parekh N, Chappell RJ, Millen AE et al. Association between vitamin D and age-related macular degeneration in the Third National Health and Nutrition Examination Survey, 1988 through 1994. Arch Ophthalmol 2007; 125: 661-669.
83. Millen AE, Voland R, Sondel SA et al. Vitamin D status and early age-related macular degeneration in postmenopausal women. Arch Ophthalmol 2011; 129: 481-489.
84. Payne JF, Ray R, Watson DG et al. Vitamin D insufficiency in diabetic retinopathy. Endocr Pract 2012; 18: 185-193.
85. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-2748.
86. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91-101.
87. Stefoni S, Cianciolo G, Donati G et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61: 324-335.
88. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol 2000; 130: 658-663.
89. Wang ZY, Zhao KK, Zhao PQ. Erythropoietin is increased in aqueous humor of glaucomatous eyes. Curr Eye Res 2010; 35: 680-684.
90. Nassiri N, Nassiri N, Majdi M et al. Erythropoietin levels in aqueous humor of patients with glaucoma. Mol Vis 2012; 18: 1991-1995.
91. Cumurcu T, Bulut Y, Demir HD et al. Aqueous humor erythropoietin levels in patients with primary open-angle glaucoma. J Glaucoma 2007; 16: 645-648.
92. Menon V, Shlipak MG, Wang X et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147: 19-27.
93. Wasselius J, Hakansson K, Johansson K et al. Identification and localization of retinal cystatin C. Invest Ophthalmol Vis Sci 2001; 42: 1901-1906.
94. Deguchi J, Yamamoto A, Yoshimori T et al. Acidification of phagosomes and degradation of rod outer segments in rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 1994; 35: 568-579.
95. Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 2005; 16: 3488-3500.
96. Klein R, Knudtson MD, Lee KE et al. Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 2009; 127: 193-199.
97. He R, Shen J, Zhao J et al. High cystatin C levels predict severe retinopathy in type 2 diabetes patients. Eur J Epidemiol 2013; 28: 775-778.
98. Jonasson F, Arnarsson A, Eiriksdottir G et al. Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study. Ophthalmology 2011; 118: 825-830.
99. Cheung CM, Tai ES, Kawasaki R et al. Prevalence of and risk factors for age-related macular degeneration in a multiethnic Asian cohort. Arch Ophthalmol 2012; 130: 480-486.
100. Mitchell P, Smith W, Attebo K et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-1460.
101. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-943.
102. Lim LS, Mitchell P, Seddon JM et al. Age-related macular degeneration. Lancet 2012; 379: 1728-1738.
103. Liew G, Mitchell P, Wong TY et al. CKD increases the risk of age-related macular degeneration. J Am Soc Nephrol 2008; 19: 806-811.
104. Nitsch D, Evans J, Roderick PJ et al. Associations between chronic kidney disease and age-related macular degeneration. Ophthalmic Epidemiol 2009; 16: 181-186.
105. Weiner DE, Tighiouart H, Reynolds R et al. Kidney function, albuminuria and age-related macular degeneration in NHANES III. Nephrol Dial Transplant 2011; 26: 3159-3165.
106. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136.
107. Chavers BM, Mauer SM, Ramsay RC et al. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994; 43: 441-446.
108. Girach A, Vignati L. Diabetic microvascular complications-can the presence of one predict the development of another? J Diabetes Complications 2006; 20: 228-237.
109. Parving HH, Hommel E, Mathiesen E et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed 1988; 296: 156-160.
110. Zander E, Seidlein I, Herfurth S et al. Increased prevalence of proliferative retinopathy and cardiovascular autonomic dysfunction in IDDM patients with proteinuria. Exp Clin Endocrinol 1992; 99: 102-107.
111. Mottl AK, Kwon KS, Garg S et al. The association of retinopathy and low GFR in type 2 diabetes. Diabetes Res Clin Pract 2012; 98: 487-493.
112. Cruickshanks KJ, Ritter LL, Klein R et al. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993; 100: 862-867.
113. Deva R, Alias MA, Colville D et al. Vision-threatening retinal abnormalities in chronic kidney disease stages 3 to 5. Clin J Am Soc Nephrol 2011; 6: 1866-1871.
114. Grunwald JE, Alexander J, Maguire M et al. Prevalence of ocular fundus pathology in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 867-873.
115. Chen YH, Chen HS, Tarng DC. More impact of microalbuminuria on retinopathy than moderately reduced GFR among type 2 diabetic patients. Diabetes Care 2012; 35: 803-808.
116. Penno G, Solini A, Zoppini G et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2012; 35: 2317-2323.
117. Liew G, Mitchell P, Wong TY et al. Retinal microvascular signs are associated with chronic kidney disease in persons with and without diabetes. Kidney Blood Press Res 2012; 35: 589-594.
118. Wong TY, Coresh J, Klein R et al. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol 2004; 15: 2469-2476.
119. Edwards MS, Wilson DB, Craven TE et al. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study. Am J Kidney Dis 2005; 46: 214-224.
120. Sabanayagam C, Shankar A, Koh D et al. Retinal microvascular caliber and chronic kidney disease in an Asian population. Am J Epidemiol 2009; 169: 625-632.
121. Gao B, Zhu L, Pan Y et al. Ocular fundus pathology and chronic kidney disease in a Chinese population. BMC Nephrol 2011; 12: 62.
122. Cook C, Foster P. Epidemiology of glaucoma: what's new? Can J Ophthalmol 2012; 47: 223-226.
123. Nongpiur ME, Wong TY, Sabanayagam C et al. Chronic kidney disease and intraocular pressure: the Singapore Malay Eye Study. Ophthalmology 2010; 117: 477-483.
124. Levy J, Tovbin D, Lifshitz T et al. Intraocular pressure during haemodialysis: a review. Eye (Lond) 2005; 19: 1249-1256.
125. Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol 2012; 27: 2205-2211.
126. Wang TJ, Wu CK, Hu CC et al. Increased risk of co-morbid eye disease in patients with chronic renal failure: a population-based study. Ophthalmic Epidemiol 2012; 19: 137-143.
127. Klein BE, Klein R, Lee KE. Renal function abnormalities and incident cataract after a five-year interval: The Beaver Dam Eye Study. Curr Eye Res 1998; 17: 720-725.
128. Huynh SC, Kifley A, Strippoli GF et al. Is renal impairment a predictor of the incidence of cataract or cataract surgery? Findings from a population-based study. Ophthalmology 2005; 112: 293-300.
129. Klein BE, Knudtson MD, Brazy P et al. Cystatin C, other markers of kidney disease, and incidence of age-related cataract. Arch Ophthalmol 2008; 126: 1724-1730.
130. Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
131. Berlyne GM, Ari JB, Danovitch GM et al. Cataracts of chronic renal failure. Lancet 1972; 1: 509-511.
132. Klaassen-Broekema N, van Bijsterveld OP. Limbal and corneal calcification in patients with chronic renal failure. Br J Ophthalmol 1993; 77: 569-571.
133. Canellos HM, Cooper J, Paek A et al. Multiple calcified deposits along the eyelid margins secondary to chronic renal failure and hyperparathyroidism. Optometry 2005; 76: 181-184.
134. Su DH, Wong TY, Foster PJ et al. Central corneal thickness and its associations with ocular and systemic factors: the Singapore Malay Eye Study. Am J Ophthalmol 2009; 147: e701.
135. Ohguro N, Matsuda M, Fukuda M. Corneal endothelial changes in patients with chronic renal failure. Am J Ophthalmol 1999; 128: 234-236.
136. Gass JD. Bullous retinal detachment and multiple retinal pigment epithelial detachments in patients receiving hemodialysis. Graefes Arch Clin Exp Ophthalmol 1992; 230: 454-458.
137. Troiano P, Buccianti G. Bilateral symmetric retinal detachment and multiple retinal pigment epithelial detachments during haemodialysis. Nephrol Dial Transplant 1998; 13: 2135-2137.
138. Ooi QL, Tow FK, Deva R et al. The microvasculature in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1872-1878.
139. Wong TY, Islam FM, Klein R et al. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci 2006; 47: 2341-2350.
140. Ikram MK, de Jong FJ, Vingerling JR et al. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 2004; 45: 2129-2134.
141. Liew G, Sharrett AR, Wang JJ et al. Relative importance of systemic determinants of retinal arteriolar and venular caliber: the atherosclerosis risk in communities study. Arch Ophthalmol 2008; 126: 1404-1410.
142. Islam FM, Nguyen TT, Wang JJ et al. Quantitative retinal vascular calibre changes in diabetes and retinopathy: the Singapore Malay eye study. Eye (Lond) 2009; 23: 1719-1724.
143. Sabanayagam C, Tai ES, Shankar A et al. Retinal arteriolar narrowing increases the likelihood of chronic kidney disease in hypertension. J Hypertens 2009; 27: 2209-2217.
144. Yau JW, Xie J, Kawasaki R et al. Retinal arteriolar narrowing and subsequent development of CKD Stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2011; 58: 39-46.
145. Sabanayagam C, Shankar A, Klein BE et al. Bidirectional association of retinal vessel diameters and estimated GFR decline: the Beaver Dam CKD Study. Am J Kidney Dis 2011; 57: 682-691.
146. Tornig J, Amann K, Ritz E et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996; 7: 667-675.
147. Amann K, Munter K, Wessels S et al. Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 2000; 11: 1702-1711.
148. Evans T, Deng DX, Chen S et al. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49: 662-666.
149. Klein R, Klein BE, Moss SE et al. Retinal vascular abnormalities in persons with type 1 diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVIII. Ophthalmology 2003; 110: 2118-2125.
150. Wong TY, Klein R, Klein BE et al. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol 2001; 46: 59-80.
151. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351: 2310-2317.
152. Klein R, Sharrett AR, Klein BE et al. Are retinal arteriolar abnormalities related to atherosclerosis?: The Atherosclerosis Risk in Communities Study. Arterioscler Thromb Vasc Biol 2000; 20: 1644-1650.
153. Myers CE, Klein R, Knudtson MD et al. Determinants of retinal venular diameter: The Beaver Dam Eye Study. Ophthalmology 2012; 119: 2563-2571.
154. Klein R, Klein BE, Moss SE et al. Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2007; 114: 1884-1892.
155. Klein R, Klein BE, Knudtson MD et al. Are inflammatory factors related to retinal vessel caliber? The Beaver Dam Eye Study. Arch Ophthalmol 2006; 124: 87-94.
156. Liew G, Mitchell P, Rochtchina E et al. Fractal analysis of retinal microvasculature and coronary heart disease mortality. Eur Heart J 2011; 32: 422-429.
157. Choi J, Moon JW, Shin HJ. Chronic kidney disease, early age-related macular degeneration, and peripheral retinal drusen. Ophthalmic Epidemiol 2011; 18: 259-263.
158. Rani PK, Raman R, Gupta A et al. Albuminuria and Diabetic Retinopathy In Type 2 Diabetes Mellitus Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 12). Diabetol Metab Syndr 2011; 3: 9.
159. Grunwald JE, Alexander J, Ying GS et al. Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) Study. Arch Ophthalmol 2012; 130: 1136-1144.
160. Sng CC, Sabanayagam C, Lamoureux EL et al. Fractal analysis of the retinal vasculature and chronic kidney disease. Nephrol Dial Transplant 2010; 25: 2252-2258.